Disrupting the market and driving life-science innovation
Infusion 51a is an impact-focused investment fund changing the healthcare game
Disrupting the market and driving life-science innovation
Infusion 51a is an impact-focused investment fund changing the healthcare game
What is Infusion 51a?
Infusion 51a is an impact investment fund facilitating the development of innovative biotech solutions.
Our team has a wealth of experience in the biotech investment arena. We connect like-minded investors with successful entrepreneurs, both driven by a desire to make the world a better place.
We’re seeking inspiring leaders – passive observers need not apply!
What is Infusion 51a?
Infusion 51a is an impact investment fund facilitating the development of innovative biotech solutions.
Our team has a wealth of experience in the biotech investment arena. We connect like-minded investors with successful entrepreneurs, both driven by a desire to make the world a better place.
We’re seeking inspiring leaders – passive observers need not apply!
Looking to invest in something that turns the odds around?
We pursue visionary investors that have unwavering confidence in the technology of tomorrow. Once we connect with the right type of investor, our team ensures capital is allocated to quickly scale revolutionary life-science technologies. All businesses Infusion 51a work with have the potential to change the future of healthcare.
Looking to invest in something that turns the odds around?
We pursue visionary investors that have unwavering confidence in the technology of tomorrow. Once we connect with the right type of investor, our team ensures capital is allocated to quickly scale revolutionary life-science technologies. All businesses Infusion 51a work with have the potential to change the future of healthcare.
We have a people-first mindset
For us, being impact-driven goes beyond investing: our organization doesn’t just elevate life-science by sourcing capital. Instead, we pay particular attention to our ability to serve the community.
Over the years, we’ve focused on oncology assets, which have brought us enormously close to the touching stories of cancer patients. Together Against Glioblastoma is an Infusion 51a-led initiative providing people with a platform where they can share experiences, receive guidance and find educational resources in their fight against the deadliest form of brain cancer.
Sometimes it’s important for people to know they are not alone and having a place to share in confidence with others can make every bit of difference!
We have a people-first mindset
For us, being impact-driven goes beyond investing: our organization doesn’t just elevate life-science by sourcing capital. Instead, we pay particular attention to our ability to serve the community.
Over the years, we’ve focused on oncology assets, which have brought us enormously close to the touching stories of cancer patients. Together Against Glioblastoma is an Infusion 51a-led initiative providing people with a platform where they can share experiences, receive guidance and find educational resources in their fight against the deadliest form of brain cancer.
Sometimes it’s important for people to know they are not alone and having a place to share in confidence with others can make every bit of difference!
A look into the biotech landscape
The size and variety of the biotech sector make it suitable for almost anyone to build a diversified portfolio. Over the past decade, investors have repeatedly profited from biotech’s limitless potential, with stocks having far outperformed the S&P 500 (Mckinsey, 2022). It‘s never too late to start — why not doing it now?
Biotechnology Global Industry Analysis and Forecast 2022 – 2030 (Precedence Research)
Biotech and Precision Medicine evolution timeline
Biotechnology has rapidly improved and changed the landscape of treatment options, with precision medicines using big data, proteomics, transcriptomic, and molecular imaging to create new systemic therapies. These advancements translate into countless opportunities for investors and, ultimately, better outcomes for patients.
of Human Genome
.
.
.
next-generation sequencer
.
.
.
announces a precision
medicine national initiative
.
.
popularization
.
.
.
Platform was launched,
offering cloud computing, diverse datasets, and
data harmonization
precision medicine
research with nearly 30
thousand written
worldwide
intelligence to enhance the
practice of laboratory
medicine
.
challenged healthcare
professionals to change
toward more personalized
approaches
treatments
.
.
.
Sources: Surgical Oncology Clinics of North America (2021), The Lancet (2021), Frontiers in Genetics (2020), BMC Medical Informatics and Decision Making (2018), International Risk Governance Council (2018)
Sources: Surgical Oncology Clinics of North America (2021), The Lancet (2021), Frontiers in Genetics (2020), BMC Medical Informatics and Decision Making (2018), International Risk Governance Council (2018)